(VIANEWS) - Digital Ally (DGLY), New York Mortgage Trust (NYMT), Tivity Health (TVTY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Digital Ally (DGLY)
149.6% sales growth and 55.1% return on equity
Digital Ally, Inc. produces and sells digital video imaging, storage, and disinfectant and related safety products for use in law enforcement, security, and commercial applications in the United States and internationally.
Digital Ally's sales growth this year is expected to be 40.8% and 145% for next year.
Year-on-year quarterly revenue growth grew by 44%, now sitting on 11.39M for the twelve trailing months.
Volume
Today's last reported volume for Digital Ally is 6495300 which is 426.43% above its average volume of 1233840.
Digital Ally's sales growth is a negative 0% for the current quarter and 149.6% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 55.1%.
Volatility
Digital Ally's last day, last week, and last month's current intraday variation average was 12.70%, 5.90%, and 3.89%, respectively.
Digital Ally's highest amplitude of average volatility was 15.32% (day), 9.90% (last week), and 6.62% (last month), respectively.
Digital Ally's Stock Yearly Top and Bottom Value
Digital Ally's stock is valued at $1.42 at 10:22 EST, way below its 52-week high of $3.98 and way higher than its 52-week low of $1.04.
Digital Ally's Moving Average
Digital Ally's worth is way higher than its 50-day moving average of $1.19 and below its 200-day moving average of $1.49.Previous days news about Digital Ally(DGLY)
- According to Benzinga on Wednesday, 17 November, "• Digital Ally (NASDAQ:DGLY) is projected to report earnings for its third quarter."
2. New York Mortgage Trust (NYMT)
36.5% sales growth and 10.12% return on equity
New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States.
New York Mortgage Trust's sales growth this year is expected to be 12.4% and 29.1% for next year.
Year-on-year quarterly revenue growth declined by 29.1%, now sitting on 320.19M for the twelve trailing months.
Volume
Today's last reported volume for New York Mortgage Trust is 1057050 which is 53.31% below its average volume of 2264090.
New York Mortgage Trust's sales growth for the next quarter is 36.5%. The company's growth estimates for the present quarter and the next is a negative 33.3% and 9.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.12%.
Volatility
New York Mortgage Trust's last day, last week, and last month's current intraday variation average was 0.70%, 1.17%, and 1.16%, respectively.
New York Mortgage Trust's highest amplitude of average volatility was 1.17% (day), 1.68% (last week), and 1.65% (last month), respectively.
New York Mortgage Trust's Stock Yearly Top and Bottom Value
New York Mortgage Trust's stock is valued at $4.30 at 10:22 EST, way under its 52-week high of $4.93 and way above its 52-week low of $2.90.
New York Mortgage Trust's Moving Average
New York Mortgage Trust's worth is below its 50-day moving average of $4.35 and below its 200-day moving average of $4.42.3. Tivity Health (TVTY)
29.3% sales growth and 165.8% return on equity
Tivity Health, Inc. provides fitness, nutrition, and social connection solutions in the United States.
Tivity Health's sales growth this year is expected to be 9.7% and 15% for next year.
Year-on-year quarterly revenue growth grew by 46.6%, now sitting on 424.26M for the twelve trailing months.
Volume
Today's last reported volume for Tivity Health is 163518 which is 50.4% below its average volume of 329682.
Tivity Health's sales growth for the next quarter is 29.3%. The company's growth estimates for the current quarter and the next is a negative 50% and negative -7.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 165.8%.
Volatility
Tivity Health's last day, last week, and last month's current intraday variation average was 0.07%, 0.56%, and 1.38%, respectively.
Tivity Health's highest amplitude of average volatility was 1.53% (day), 2.25% (last week), and 3.44% (last month), respectively.
Tivity Health's Stock Yearly Top and Bottom Value
Tivity Health's stock is valued at $27.59 at 10:22 EST, under its 52-week high of $29.18 and way above its 52-week low of $15.36.
Tivity Health's Moving Average
Tivity Health's value is above its 50-day moving average of $25.16 and way higher than its 200-day moving average of $24.73.4. Catalyst Pharmaceuticals (CPRX)
15.6% sales growth and 49.72% return on equity
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
Catalyst Pharmaceuticals's sales growth this year is anticipated to be 14.1% and 20.3% for next year.
Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.
Volume
Today's last reported volume for Catalyst Pharmaceuticals is 66433 which is 92.54% below its average volume of 890987.
Catalyst Pharmaceuticals's sales growth for the next quarter is 15.6%. The company's growth estimates for the current quarter and the next is a negative 75.6% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 49.72%.
Volatility
Catalyst Pharmaceuticals's last day, last week, and last month's current intraday variation average was 1.11%, 4.38%, and 2.39%, respectively.
Catalyst Pharmaceuticals's highest amplitude of average volatility was 8.78% (day), 8.18% (last week), and 4.45% (last month), respectively.
Catalyst Pharmaceuticals's Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals's stock is valued at $7.33 at 10:22 EST, higher than its 52-week high of $7.32.
Catalyst Pharmaceuticals's Moving Average
Catalyst Pharmaceuticals's value is way higher than its 50-day moving average of $5.85 and way higher than its 200-day moving average of $5.56.5. Harrison (K.J.) & Partners, Inc. (AEE)
5.9% sales growth and 10.4% return on equity
Harrison (K.J.) & Partners, Inc.'s sales growth this year is anticipated to be 6.1% and 4.4% for next year.
Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 5.74B for the twelve trailing months.
Volume
Today's last reported volume for Harrison (K.J.) & Partners, Inc. is 93057 which is 90.57% below its average volume of 987378.
Harrison (K.J.) & Partners, Inc.'s sales growth for the next quarter is 5.9%. The company's growth estimates for the current quarter and the next is 8.8% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.4%.
Volatility
Harrison (K.J.) & Partners, Inc.'s last day, last week, and last month's current intraday variation average was 0.76%, 0.96%, and 0.77%, respectively.
Harrison (K.J.) & Partners, Inc.'s highest amplitude of average volatility was 1.30% (day), 1.27% (last week), and 1.48% (last month), respectively.
Harrison (K.J.) & Partners, Inc.'s Stock Yearly Top and Bottom Value
Harrison (K.J.) & Partners, Inc.'s stock is valued at $85.05 at 10:22 EST, under its 52-week high of $90.77 and way higher than its 52-week low of $69.79.